12:00 AM
May 17, 2010
 |  BC Week In Review  |  Company News  |  Deals

Peregrine, Stason Pharmaceuticals Inc. deal

Peregrine granted Stason exclusive rights to develop and commercialize its tumor necrosis therapy (TNT) technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. The deal includes exclusive rights to Cotara, an Iodine 131...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >